Follow us:

科研产品

  • 基因表达PCR芯片
  • 体细胞突变PCR芯片
  • 拷贝数变化PCR芯片
  • 基因分型PCR芯片
  • 蛋白表达抗体芯片
  • 蛋白磷酸化抗体芯片
  • 蛋白质相互作用芯片
  • 引物和探针
  • 常规分子生物学试剂

  • 临床产品

  • 个性化用药
  • 易感基因检测
  • 生物标志物试剂盒

  • > 产品目录 > 科研产品 > 体细胞突变PCR芯片 > 皮肤癌体细胞突变PCR芯片
    人皮肤癌体细胞突变PCR芯片适用于快速、准确的进行皮肤癌相关基因突变的检测,包括:BRAF, CDKN2A, CTNNB1/beta-catenin, FGFR3, GNAQ, HRAS, KIT, KRAS, NRAS, PIK3CA, PTCH1, PTEN, RB1, SMO, LKB1/STK11, 和P53。对上述基因突变的深入研究有助于科研工作者更好的了解肿瘤的发生机制,并为临床靶向用药提供可靠的分子机理。
    皮肤癌体细胞突变PCR芯片
    人皮肤癌体细胞突变PCR芯片适用于快速、准确的进行皮肤癌相关基因突变的检测,包括:BRAF, CDKN2A, CTNNB1/beta-catenin, FGFR3, GNAQ, HRAS, KIT, KRAS, NRAS, PIK3CA, PTCH1, PTEN, RB1, SMO, LKB1/STK11, 和P53。对上述基因突变的深入研究有助于科研工作者更好的了解肿瘤的发生机制,并为临床靶向用药提供可靠的分子机理。利用单个或多个体细胞突变信息检测关键信号通路异常已被广泛应用于临床研究。例如: EGFR和KRAS基因突变能够预测靶向该位点的药物治疗响应。人皮肤癌体细胞突变PCR芯片覆盖广泛,适用于皮肤癌以及含有此类突变的其他肿瘤的突变检测,并有望为临床相关疾病提供潜在药物治疗靶点。该芯片包含78个皮肤癌中最常见的,并具有重要功能和生理学意义的突变位点。突变位点主要由多种体细胞突变数据库以及经同行评阅的科学文献筛选得到,展示了超过7100例皮肤癌患者的最常见突变。

    Assay functional annotations
    BRAF: 7 Assays
    There are two major classes of BRAF mutations. One class leads to increased BRAF kinase activity, such as the p. V600E mutation. The other class leads to impaired kinase activity, such as the p.G469A mutation.
    CDKN2A: 7 Assays
    The top CDKN2A loss-of-function mutations occur in the consensus ankyrin domain, which leads to inability to form stable complexes with its targets.
    CTNNB1: 8 Assays
    The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
    FGFR3: 6 Assays
    The most frequently identified mutations occur in the kinase domain and non-kinase extracellular domains such as the hinge region and IgG-like domain. Some of the somatic mutations also correspond to congenital SNPs involved in genetic diseases.
    GNAQ: 3 Assays
    The mutations queried by these assays all lie in the protein's GTP nucleotide binding domain.
    HRAS: 8 Assays
    The mutation assays include the most important HRAS mutations identified in cancers at codons 12, 13, and 61.
    KIT: 2 Assays
    The most frequently identified KIT gain-of-function mutations include the D816V point mutation, the exon 11 (juxtamembrane domain) deletion and point mutations, an exon 9 insertion mutation, and exon 13 point mutations.
    KRAS: 3 Assays
    The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
    NRAS: 11 Assays
    The mutation assays include the most important NRAS mutations at codons 12, 13, and 61.
    PIK3CA: 3 Assays
    The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
    PTCH1: 3 Assays
    Mutations in this gene constitutively activate the WNT signaling pathway and the GLI transcription factors increasing the expression of genes involved in tumor cell growth, differentiation, and proliferation.
    PTEN: 1 Assay
    The most commonly detected PTEN loss-of-function mutations are due to either truncation (p.R233* and p.R130*) or point mutations causing phosphatase inactivation (p.R130 and p.R173 mutations).
    RB1: 1 Assay
    The highly recurrent RB loss of tumor suppressor function mutations are either due to truncation or disruption of binding partner interactions.
    SMO: 1 Assay
    Mutations in this gene constitutively activate the WNT signaling pathway and the GLI transcription factors increasing the expression of genes involved in tumor cell growth, differentiation, and proliferation.
    STK11: 1 Assay
    The most commonly detected STK11/LKB1 inactivation mutations are mainly due to truncation or point mutations.
    TP53: 13 Assays
    The most frequently detected somatic mutations in TP53 are largely composed of DNA-binding domain mutations which disrupt either DNA binding or protein structure.
    规格:78个位点/array    1sample/array
    灵敏度:低至0.1%的体细胞突变


    更多了解产品和解决方案>>
    美好杏园你我共创